Directory → Organotropona funds → Cardiovascular funds → Receptor antagonists angiotenzina II (At_1-podtip) → Aprovel
This page is translated automatically with a help of Google Translate

Aprovel

See also Irbesartan

Roman name

Aprovel

The composition and the form of

Pill-1 tabl.irbesartan-150 or 300 megawatts blistere 14 pcs. ; In a Box 1, 2 or 4 blisters.

Pharmacokinetics

Once inside well absorbed from the digestive tract. C_max achieved through 1.5-2 hours Bioavailability of 60-80%, tying with the plasma protein-96% of the K-l T_1/2 - 11-15 hours Metabolised in the liver by oxidation and conjugation with glukuronova acid (major metabolite - glukuronid irbesartan, which is the concentration in the blood-6%). Return with urine (20%, of which less than 2% in an unmodified form), and faeces.

Farmakodinamika

Alleviate sossoudossouerveshchee the angiotenzina II; Reduces round, postnagruzku, AD system and the pressure on a small range of diseases.

Clinical pharmacology

The maximum effect is the 3-6 h after a single reception. Gipotenzivne to be maintained for a period of 24 hours Clinical effects are achieved in 1-2 weeks CAD application. Do not change the concentration of triglycerides, cholesterol, glucose and uric acid in the plasma and the development of uric acid in urine.

Indications

Arterial hypertension.

Pregnancy and lactation

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Contraindications

Hypersensitivity, pregnancy, the breast вскармливания.Возрас�� up to 18 years of age (the effectiveness and safety have not been established).

Side-Effects

Headache, dizziness, nausea, vomiting, malaise, weakness, side effects typically are poorly and were temporary.

Patient interaction

Tiazidnye dioretiki increase gipotenzivne effect.

Precautions

With dehydration, giponatriemii (dioretikami treatment, restriction of salt diet, diarrhoea, vomiting), a decrease in dose. To apply caution in patients with unilateral or bilateral renal stenosis arteries in acute renal failure, or aortalnam mitralnam stenosis, obstructive gipertroficescoy cardiomiopatiei (requires monitoring of potassium and creatinine in serum).

Storage conditions

List B. In dry place at a temperature below 30 ° C

Shelf life

3 years

The registration

014945/01-2003

All products of this group